Recent research on Frizzled 7(FZD7), a G protein-coupled receptor (GPCR) in the Frizzled family, has unveiled new structural insights that could guide the development of future drugs targeting intestinal tumors. FZD7 is known for its role in the renewal of intestinal stem cells and has been implicated in the development and proliferation of tumors in the gastrointestinal tract. Understanding the structural basis of its activation and regulation opens new avenues for designing drugs that can selectively target these receptors and potentially inhibit tumor growth.
Understanding Frizzled 7 (FZD7) and Its Role in Tumor Development
Frizzleds (FZDs) are a subfamily of Class F GPCRs involved in critical signaling pathways, including Wnt/β-catenin, which are vital for embryonic development, cell differentiation, and tissue homeostasis. Among the ten paralogs, FZD7 stands out due to its specific involvement in mesendodermal cell migration, stem cell renewal, and its crucial role in the turnover of adult intestinal epithelium. Its upregulation is frequently observed in various cancers, particularly in colorectal cancer, where it drives tumor proliferation, metastasis, maintenance of cancer stem cells, and resistance to chemotherapy.
The study reports that FZD7 is highly expressed in cancer cell lines with mutations in APC or CTNNB1, key genes in colorectal cancer. When FZD7 is knocked down using small interfering RNA (siRNA), there is a significant decrease in the viability and invasive potential of these cancer cells. This makes FZD7 an attractive target for cancer therapy, specifically in the context of gastrointestinal tumors.
Structural Insights into FZD7 and Allosteric Regulation
The recent study, using cryo-electron microscopy (cryo-EM), has determined the structure of the inactive FZD7 at a high resolution of 1.9 Å. The structural analysis revealed a fluctuating water pocket in the receptor core that is critical for its dynamics and activation. This water network within FZD7 is comparable to those found in other GPCR classes and is believed to be essential for the receptor's stability and conformational changes during activation. The study utilized molecular dynamics simulations to explore how water molecules within this pocket influence potential conformational shifts, which could impact receptor activation and signaling.
Moreover, the research identifies a conserved cholesterol-binding site within FZD7 that plays a crucial role in its association with Disheveled (DVL), a protein that initiates downstream signaling cascades, including Wnt/β-catenin. The presence of this cholesterol-binding site was confirmed through mutagenesis and bioluminescence resonance energy transfer (BRET) assays, which demonstrated that disrupting this site affects FZD7's ability to interact with DVL, thereby impacting its signaling capabilities.
Implications for Drug Development
The detailed understanding of FZD7's structure, particularly its internal water pocket and cholesterol-binding site, offers a foundation for developing drugs that can selectively modulate this receptor's activity. Targeting the cholesterol-binding site or manipulating the water network within the receptor core could lead to novel therapeutic strategies that inhibit FZD7-mediated signaling pathways in cancer cells.
Additionally, the study suggests that the structural features of FZD7 provide potential for the development of allosteric modulators—compounds that bind to a site other than the active site and modify receptor activity. Such drugs could offer more precise control over FZD7's function, reducing the likelihood of side effects associated with more generalized receptor inhibition.
Conclusion
This breakthrough in understanding the structural basis of FZD7 activation and regulation highlights new possibilities for developing targeted therapies against intestinal tumors. By focusing on the unique structural features of FZD7, including its water pocket dynamics and cholesterol-binding site, researchers can design drugs that selectively inhibit tumor-promoting pathways. This approach not only holds promise for treating colorectal cancer but also for broader applications in oncology, where GPCRs like FZD7 play pivotal roles in disease progression.
Source: https://www.nature.com/articles/s41467-024-51664-4
English (United States) ·